4. Insulet
R&D spend: $55.7 million
Percent of revenues: 15.2%
2017 overall revenue rank: 87
Insulet (Nasdaq: PODD) seeks to expand the use of insulin pump therapy for diabetes through its Omnipod insulin management system. Billerica, Mass.–based Insulet touts the Omnipod system as an easy-to-use tubeless insulin pump. It provides up to three days of non-stop insulin delivery, and users don’t need to handle a needle.